KMT2A and acute myeloid leukemia: Jiang et al., identified two compounds (i.e., NSC-311,068 and NSC-370,284) that selectively suppress TET1 transcription and 5hydroxymethylcytosine (5hmC) modification, that effectively inhibit cell viability in AML with high expression of TET1, including AML with MLL rearrangements and t(8;21).